Oral delivery of hematopoietic factors: Progress with gastrointestinal mucoadhesive patches, microdevices, and other microfabrication technologies

American Journal of Drug Delivery

Volumn 4, Issue 2, 2006, Pages 65-77

  Takada, Kanji ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLCARNITINE; AMPICILLIN; APROTININ; BUSERELIN; CALCITONIN; CAP; CARBOXYLIC ACID; CASEIN; CEFAZOLIN; CELLACEFATE; CHITOSAN DERIVATIVE; CHYMOTRYPSIN INHIBITOR; CYANOCOBALAMIN; ERYTHROPOIETIN; EUDRAGIT; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; HYDROXYPROPYLMETHYLCELLULOSE PHTHALATE; INSULIN; LABRASOL; LIPOSOME; LOW MOLECULAR WEIGHT HEPARIN; NANOCAPSULE; OVALBUMIN; PROTEINASE INHIBITOR; RICINOMACROGOL; SOYBEAN TRYPSIN INHIBITOR; SURFACTANT; UNINDEXED DRUG; WATER;

COLON; DIFFUSION; DILUTION; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG INHIBITION; DRUG RELEASE; DRUG SOLUBILITY; DRUG SYNTHESIS; EMULSION; GASTROINTESTINAL MUCOADHESIVE PATCH SYSTEM; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TRACT; HUMAN; HYDROLYSIS; INTESTINE CELL; LEUKOCYTE COUNT; MEMBRANE PERMEABILITY; MICROCAPSULE; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW; SMALL INTESTINE; TABLET;

EID: 33745907806     PISSN: 11759038     EISSN: 11759038     Source Type: Journal    
DOI: 10.2165/00137696-200604020-00002     Document Type: Review

References (90)

1. Crommelin DJ, Sindelar RD. Pharmaceutical biotechnology. Amsterdam: Harwood Academic Publishers, 1997
2. Szkrybalo W. Emerging trends in biotechnology: a perspective from the pharmaceutical industry. Pharm Res 1987; 4: 361-3
3. Bienz-Tadmor B. Biopharmaceuticals go to market: patterns of worldwide development. Biotechnology (NY) 1993; 11: 168-72
4. Drews J. Intent and coincidence in pharmaceutical discovery: the impact of biotechnology. Arznmittel Forschung 1995; 45: 934-9
5. Vermeij P, Blok D. New peptide and protein drugs. Pharm World Sci 1996; 18: 87-93
6. Wilding IR, Davis SS, O'Hagan DT. Targeting of drugs and vaccines to the gut. Pharmacol Ther 1994; 62: 97-124
7. Zhou XH. Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs. J Control Release 1994; 29: 239-52
8. Healey JNC. Enteric coatings and delayed release. In: Hardy JG, Davis SS, Wilson CG, editors. Drug delivery to the gastrointestinal tract. New York: John Wiley & Sons, 1989: 83-96
9. Gomez-Orellana I, Paton DR. Advances in the oral delivery of proteins. Exp Opin Ther Patents 1998; 8: 223-34
10. Shah RB, Ahsan F, Khan MA. Oral delivery of proteins: progress and prognostication. Crit Rev Ther Drug Carrier Syst 2002; 19: 135-69
11. Sayani AP, Chien YW. Systemic delivery of peptides and proteins across absorptive mucosae. Crit Rev Ther Drug Carrier Syst 1996; 13: 85-184
12. Iwabuchi A, Makino K, Kanda M. Influence of gastrointestinal microflora on digestibility and biological value of protein in rats. J Nutr Sci Vitaminol (Tokyo) 1993; 39: 489-96
13. Bai JPF. Colonic delivery of peptide and protein drugs: consideration of intracellular proteolytic enzymes. STP Pharma Sci 1995; 5: 30-5
14. Bai JPF. Distribution of brush-border membrane peptidases along the rat intestine. Pharm Res 1994; 11: 897-900
15. Bai JPF. Subcellular distribution of proteolytic activities degrading bioactive peptides and analogues in the rat small intestinal and colonic enterocytes. J Pharm Pharmacol 1994; 46: 671-5
16. Michael S, Thöle M, Dillmann R, et al. Improvement of intestinal peptide absorption by a synthetic bile acid derivative, cholylsarcosine. Eur J Pharm Sci 2000; 10: 133-40
17. Chao AC, Nguyen JV, Broughall M, et al. In vitro and in vivo evaluation of effects of sodium caprate on enteral peptide absorption and on mucosal morphology. Int J Pharm 1999; 191: 15-24
18. Hochman J, Artursson P. Mechanisms of absorption enhancement and tight junction regulation. J Control Release 1994; 29: 253-67
19. Lo YL, Huang JD. Effects of sodium deoxycholate and sodium caprate on the transport of epirubicin in human intestinal epithelial caco-2 cell layers and everted gut sacs of rats. Biochem Pharmacol 2000; 59: 665-72
20. Mesiha M, Plakogiannis F, Vejosoth S. Enhanced oral absorption of insulin from desolvated fatty acid-sodium glycocholate emulsions. Int J Pharm 1994; 111: 213-6
21. Rivera TM, Leone-Bay A, Paton DR, et al. Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl) amino] caprylate: pharmacological considerations. Pharm Res 1997; 14: 1830-4
22. Amidon GL, Lennernas H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-20
23. Rinaki E, Valsami G, Macheras P. Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio. Pharm Res 2003; 20: 1917-25
24. Dantzig AH. Oral absorption of β-lactams by intestinal peptide transport proteins. Adv Drug Deliv Rev 1997; 23: 63-76
25. Lee VHL, Yamamoto A, Kompella UB. Mucosal penetration enhancers for facilitation of peptide and protein drug absorption. Crit Rev Ther Drug Carrier Syst 1991; 8: 91-192
26. Schreier S, Malheiros SVP, de Paula E. Surface active drugs: self-association and interaction with membranes and surfactants: physicochemical and biological aspects. Biochem Biophys Acta 2000; 1508: 210-34
27. Takada K, Ushirogawa Y. Effect of pH, dietary proteins and trypsin inhibitors on the hydrolytic rates of human granulocyte colony-stimulating factor (G-CSF) by rat digestive enzymes. J Pharmacobiodyn 1991; 14: 363-70
28. Ushirogawa Y, Nakahigashi Y, Kiriyama A, et al. Effect of organic acids, trypsin inhibitors and dietary protein on the pharmacological activity of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats. Int J Pharm 1992; 81: 133-41
29. Friedman DI, Amidon GL. Oral absorption of peptides: influence of pH and inhibitors on the intestinal hydrolysis of leu-enkephalin and analogues. Pharm Res 1991; 8: 93-6
30. Ohtani S, Ogawara K, Higaki K, et al. Casein enhances stability of peptides in intestinal lumen: role of digested products of casein. Pharm Res 2003; 20: 1746-51
31. Fujii S, Yokoyama T, Ikegaya Y, et al. Promoting effect of the new chymotrypsin inhibitor FK-448 on the intestinal absorption of insulin in rats and dogs. J Pharm Pharmacol 1985; 37: 545-9
32. Liu H, Tang R, Pan W, et al. Potential utility of various protease inhibitors for improving the intestinal absorption of insulin in rats. J Pharm Pharmacol 2003; 55: 1523-9
33. Bai JPF. Effects of bile salts on brush-border and cytosolic proteolytic activities of intestinal enterocytes. Int J Pharm 1994; 111: 147-52
34. Shah RB, Khan MA. Protection of salmon calcitonin breakdown with serine proteases by various ovomucoid species for oral drug delivery. J Pharm Sci 2004; 93: 392-406
35. Cho MJ, Scieszka JF, Burton PS. Citric acid as an adjuvant for transepithelial transport. Int J Pharm 1989; 52: 79-81
36. Hayashi M, Sakai T, Hasegawa T, et al. Physiological mechanism for enhancement of paracellular drug transport. J Control Release 1999; 62: 141-8
37. Unigene Inc [online]. Available from URL: http://www.unigene.com/ [Accessed 2004]
38. Nishimura K, Nozaki Y, Yoshimi A, et al. Studies on the promoting effects of carboxylic acid derivatives on the rectal absorption of β-lactam antibiotics in rats. Chem Pharm Bull (Tokyo) 1985; 33: 282-91
39. Fix JA, Gardner CR. Rectal drug delivery: a viable alternative? Pharm Int 1986; 272-5
40. Hoogdalem EJV, Stijnen AM, Boer AGD, et al. Rate-controlled absorption enhancement of rectally administered cefazolin in rats by a glyceride mixture (MGK). J Pharm Pharmacol 1988; 40: 329-32
41. Anderberg EK, Lindmark T, Artursson P. Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route. Pharm Res 1993; 10: 857-64
42. Shima M, Kimura Y, Adachi S, et al. Recovery of caco-2 cell monolayers to normal from the transport-enhanced state induced by capric acid sodium salt and its monoacylglycerol. Biosci Biotechnol Biochem 1999; 63: 680-7
43. Thanou M, Verhoef JC, Junginger HE. Trimethylated chitosan derivatives are effective and safe penetration enhancers for oral peptide drug delivery and absorption. S T P Pharm Sci 2000; 10: 315-9
44. Thanou M, Verhoef JC, Junginger HE. Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev 2001; 52: 117-26
45. Mizuno A, Ueda M, Kawanishi G. Effects of salicylate and other enhancers on rectal absorption of erythropoietin in rats. J Pharm Pharmacol 1992; 44: 570-3
46. Moriya H, Maitani Y, Shimoda N, et al. Pharmacokinetic and pharmacological profiles of free and liposomal recombinant human erythropoietin after intravenous and subcutaneous administrations in rats. Pharm Res 1997; 14: 1621-8
47. Maitani Y, Morita H, Shimoda N, et al. Distribution characteristics of entrapped recombinant human erythropoietin in liposomes and its intestinal absorption in rats. Int J Pharm 1999; 185: 13-22
48. Maitani Y, Hazawa M, Tojo Y, et al. Oral administration of recombinant human erythropoietin in liposomes in rats: influence of lipid composition and size of liposomes on bioavailability. J Pharm Sci 1996; 85: 440-5
49. Patel HM, Stevenson RW, Parson JA, et al. Use of liposomes to acid intestinal absorption of entrapped insulin in normal and diabetic dogs. Biochim Biophys Acta 1982; 716: 186-93
50. Brayden DJ, O'Mahony DJ. Novel oral drug delivery gateways for biotechnology products: polypeptides and vaccines. Pharm Sci Technol Today 1998; 7: 291-9
51. Woodley JF. Liposomes for oral administration of drugs. Crit Rev Ther Drug Carrier Syst 1985; 2: 1-18
52. Choudhari KB, Labhasetwar V, Dorle AK. Liposomes as a carrier for oral administration of insulin: effect of formulation factors. J Microencapsul 1994; 11: 319-25
53. Mathiowitz E, Jacob JS, Jong YS, et al. Biologically erodible microspheres as potential oral drug delivery systems. Nature 1997; 386: 410-4
54. Eyles JE, Alpar HO, Conway BR, et al. Oral delivery of poly(lactic acid) microsphere-encapsulated interferon in rats. J Pharm Pharmacol 1997; 49: 669-74
55. Jenkins PG, Howard KA, Blackhall NW, et al. The quantitation of the absorption of microparticles into the intestinal lymph of Wistar rats. Int J Pharm 1994; 102: 261-6
56. Sinko PJ, Lee Y-H, Makhey V, et al. Biopharmaceutical approach for developing and assessing oral peptide delivery strategies and systems: in vitro permeability and in vivo oral absorption of salmon calcitonin (sCT). Pharm Res 1999; 16: 527-33
57. Lee YH, Perry B, Sutyak JP, et al. Regional differences in intestinal spreading and pH recovery and the impact on salmon calcitonin absorption in dogs. Pharm Res 2000; 17: 284-90
58. Johnston TP, Rahman A, Alur H, et al. Permeation of unfolded basic fibroblast growth factor (bFGF) across rabbit buccal mucosa: does unfolding of bFGF enhance transport? Pharm Res 1998; 15: 246-53
59. Jensen-Pippo KE, Whitcomb KL, DePrince RB, et al. Enteral bioavailability of human granulocyte colony stimulating factor conjugated with poly(ethylene glycol). Pharm Res 1996; 13: 102-7
60. 12 mediated oral delivery systems for granulocyte-colony stimulating factor and erythropoietin. Bioconjug Chem 1995; 6: 459-65
61. 12-mediated uptake of erythropoietin and granulocyte colony stimulating factor in vitro and in vivo. Int J Pharm 1996; 145: 1-8
62. Lim C-J, Shen W-C. Comparison of monomeric and oligomeric transferring as potential carrier in oral delivery of protein drugs. J Control Release 2005; 106: 273-86
63. Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992; 9: 249-304
64. 12 conjugates to deliver protein drugs by the oral route. Crit Rev Ther Drug Carrier Syst 1998; 15: 557-86
65. Hovgaard D, Mortensen BT, Schifter S, et al. Comparative pharmacokinetics of single-dose administration of mammalian and bacterially-derived recombinant human granulocyte-macrophage colony-stimulating factor. Eur J Haematol 1993; 50: 32-6
66. Wilding I. Site-specific drug delivery in the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst 2000; 17: 557-620
67. Saffran M, Kumar GS, Savariar C, et al. A new approach to the oral administration of insulin and other peptide drugs. Science 1986; 233: 1081-4
68. Van den Mooter G, Maris B, Samyn C, et al. Use of azo polymers for colon-specific drug delivery. J Pharm Sci 1997; 86: 1321-7
69. Ashford M, Fell JT. Targeting drugs to the colon: delivery systems for oral administration. J Drug Target 1994; 2: 241-58
70. Haupt S, Rubinstein A. The colon as a possible target for orally administered peptide and protein drugs. Crit Rev Ther Drug Carrier Syst 2002; 19: 499-551
71. Fish NW, Bloor JR. Drug delivery to the colon. Exp Opin Ther Patents 1999; 9: 1515-21
72. Niwa K, Takaya T, Morimoto T, et al. Preparation and evaluation of a time-controlled release capsule made of ethylcellulose for colon delivery of drugs. J Drug Target 1995; 3: 83-9
73. Takaya T, Ikeda C, Imagawa N, et al. Development of a colon delivery capsule and the pharmacological activity of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in beagle dogs. J Pharm Pharmacol 1995; 47: 474-8
74. Stevens HNE, Wilson CG, Welling PG, et al. Evaluation of Pulsincap™ to provide regional delivery of dofetilide to the human GI tract. Int J Pharm 2002; 236: 27-34
75. Wilson CG, Bakhshaee M, Stevens HNE, et al. Evaluation of a gastro-resistant pulsed release delivery system (Pulsincap™) in humans. Drug Deliv 1997; 4: 201-6
76. Dorkoosh FA, Verhoef JC, Borchard G, et al. Development and characterization of a novel peroral peptide drug delivery system. J Control Release 2001; 71: 307-18
77. Dorkoosh FA, Verhoef JC, Verheijden JHM, et al. Peroral absorption of octreotide in pigs formulated in delivery systems on the basis of superporous hydrogel polymers. Pharm Res 2002; 19: 1532-6
78. Dorkoosh FA, Verhoef JC, Borchard G, et al. Intestinal absorption of human insulin in pigs using delivery systems based on superporous hydrogel polymers. Int J Pharm 2002; 247: 47-55
79. Schnurch B, Walker G. Multifunctional matrices for oral peptide delivery. Crit Rev Ther Drug Carrier Syst 2001; 18: 459-501
80. Eiamtrakarn S, Itoh Y, Kishimoto J, et al. Gastrointestinal mucoadhesive patch system (GI-MAPS) for oral administration of G-CSF, a model protein. Biomaterials 2002; 23: 145-52
81. Takada K, Venkatesan N. Oral administration of erythropoietin (EPO) using gastro-intestinal mucoadhesive patch system (GI-MAPS). Proceedings of 2004 AAPS Annual Meeting; 2004 Nov 10; Baltimore (MD).
82. Whitehead K, Shen Z, Mitragotri S. Oral delivery of macromolecules using intestinal patches: applications for insulin delivery. J Control Release 2004; 98: 37-45
83. Eaimtrakarn S, Itoh Y, Kishimoto J, et al. Retention and transit of intestinal mucoadhesive films in rat small intestine. Int J Pharm 2001; 224: 61-7
84. Eaimtrakarn S, Rama Prasad YV, Puthli SP, et al. Evaluation of gastrointestinal transit characteristics of oral patch preparation using caffeine as a model drug in human volunteers. Drug Metab Pharmacokinet 2002; 17: 284-91
85. Shen Z, Mitragotri S. Intestinal patches for oral drug delivery. Pharm Res 2002; 19: 391-5
86. Ahmed A, Bonner C, Desai TA. Bioadhesive microdevices with multiple reservoirs: a new platform for oral drug delivery. J Control Release 2002; 81: 291-306
87. Tao SL, Lubeley MW, Desai TA. Bioadhesive poly(methyl methacrylate) microdevices for controlled drug delivery. J Control Release 2003; 88: 215-28
88. Lehr C-M. Bioadhesion technology for the delivery of peptide and protein drugs to the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst 1994; 11: 119-60
89. Tao SL, Desai TA. Gastrointestinal patch systems for oral drug delivery. Drug Discov Today 2005; 10: 909-15
90. Venkatesan N, Yoshimitsu J, Ito Y, et al. Liquid filled nanoparticles as a drug delivery tool for protein therapeutics. Biomaterials 2005; 26: 7154-63